News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
48,734 Results
Type
Article (2460)
Company Profile (311)
Press Release (45963)
Multimedia
Podcasts (12)
Webinars (1)
Section
Business (21316)
Career Advice (94)
Deals (3519)
Drug Delivery (44)
Drug Development (6215)
Employer Resources (7)
FDA (895)
Job Trends (1347)
News (28342)
Policy (1531)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (3)
2027 Biotech Beach Standard (4)
2027 Genetown Elite (5)
2027 Genetown Standard (8)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (7)
Academia (124)
Academic (1)
Accelerated approval (6)
ADA (1)
Adcomms (7)
Allergies (17)
Alliances (1368)
ALS (72)
Alzheimer's disease (229)
Antibody-drug conjugate (ADC) (89)
Approvals (1027)
Artificial intelligence (57)
ASCO (49)
Autoimmune disease (39)
Automation (5)
Bankruptcy (11)
Best Places to Work (1280)
BIO (2)
Biologics (1)
BIOSECURE Act (3)
Biosimilars (28)
BioSpace Insights (19)
Biotechnology (223)
Bispecific (1)
Bladder cancer (34)
Brain cancer (5)
Breast cancer (121)
Cancer (771)
Cardiovascular disease (47)
Career advice (92)
Career pathing (5)
CAR-T (29)
CDC (2)
CDMO (156)
Celiac Disease (1)
Cell therapy (92)
Cervical cancer (11)
Clinical research (6044)
Collaboration (134)
Commercialization (2)
Compensation (116)
Complete response letters (8)
COVID-19 (169)
CRISPR (10)
C-suite (56)
Cystic fibrosis (10)
Data (1130)
Denatured (1)
Depression (20)
Dermatology (21)
Diabetes (49)
Diagnostics (529)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (3)
Drug discovery (28)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (13)
Earnings (19529)
Editorial (8)
Employer branding (2)
Employer resources (9)
Events (5734)
Executive appointments (46)
FDA (1474)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (1)
Frontotemporal dementia (14)
Funding (109)
Gene editing (18)
Generative AI (8)
Gene therapy (73)
GLP-1 (130)
Government (227)
Guidances (208)
Healthcare (1514)
Hematology (14)
HIV (6)
Huntington's disease (8)
IgA nephropathy (12)
Immunology and inflammation (22)
Immuno-oncology (9)
Indications (32)
Infectious disease (206)
Inflammatory bowel disease (23)
Influenza (11)
Intellectual property (8)
Interviews (10)
IPO (2796)
IRA (7)
Job creations (191)
Job search strategy (78)
JPM (53)
Kidney cancer (4)
Kidney disease (10)
Labor market (21)
Layoffs (67)
Leadership (4)
Legal (234)
Licensing (2)
Liver cancer (9)
Longevity (2)
Lung cancer (179)
Lymphoma (83)
Machine learning (4)
Management (1)
Manufacturing (116)
Marketing (1)
MASH (33)
Medical device (1116)
Medtech (1132)
Mergers & acquisitions (834)
Metabolic disorders (187)
mRNA (112)
Multiple sclerosis (24)
NASH (3)
Neurodegenerative disease (68)
Neuropsychiatric disorders (12)
Neuroscience (471)
NextGen: Class of 2026 (538)
Non-profit (184)
Now hiring (10)
Obesity (105)
Opinion (28)
Ovarian cancer (26)
Pain (21)
Pancreatic cancer (22)
Parkinson's disease (37)
Partnered (4)
Patents (37)
Patient recruitment (35)
Peanut (5)
People (1322)
Pharmaceutical (50)
Pharmacy benefit managers (1)
Phase 1 (1376)
Phase 2 (2514)
Phase 3 (2636)
Pipeline (2121)
Policy (25)
Postmarket research (219)
Preclinical (328)
Prostate cancer (35)
Psychedelics (11)
Radiopharmaceuticals (31)
Rare diseases (126)
Real estate (180)
Recruiting (3)
Regulatory (1572)
Reports (13)
Research institute (111)
Resumes & cover letters (7)
Rett syndrome (6)
RNA editing (9)
RSV (17)
Schizophrenia (40)
Series A (16)
Series B (7)
Service/supplier (12)
Sickle cell disease (14)
Special edition (7)
Spinal muscular atrophy (6)
Sponsored (2)
Startups (117)
Stomach cancer (3)
Substance use disorders (2)
Supply chain (12)
Tariffs (8)
The Weekly (11)
Vaccines (129)
Venture capital (16)
Weight loss (82)
Women's health (19)
Worklife (4)
Date
Last 7 days (43)
Last 30 days (162)
Last 365 days (3371)
2026 (2353)
2025 (3656)
2024 (4386)
2023 (4355)
2022 (4548)
2021 (4696)
2020 (4283)
2019 (2944)
2018 (2311)
2017 (2190)
2016 (1392)
2015 (1728)
2014 (1158)
2013 (714)
2012 (885)
2011 (1083)
2010 (914)
Location
Africa (64)
Alabama (3)
Alaska (1)
Arizona (21)
Arkansas (1)
Asia (2544)
Australia (380)
California (1647)
Canada (363)
China (144)
Colorado (84)
Connecticut (89)
Delaware (88)
Europe (7519)
Florida (247)
Georgia (92)
Hawaii (1)
Idaho (1)
Illinois (136)
India (8)
Indiana (100)
Iowa (1)
Japan (95)
Kansas (21)
Kentucky (11)
Louisiana (11)
Maine (18)
Maryland (192)
Massachusetts (1432)
Michigan (40)
Minnesota (93)
Mississippi (1)
Missouri (8)
Montana (2)
Nebraska (4)
Nevada (15)
New Hampshire (8)
New Jersey (611)
New Mexico (1)
New York (462)
North Carolina (220)
Northern California (844)
Ohio (37)
Oregon (2)
Pennsylvania (353)
Puerto Rico (1)
Rhode Island (3)
South America (81)
South Carolina (3)
Southern California (578)
Tennessee (20)
Texas (255)
United States (6375)
Utah (62)
Virginia (24)
Washington D.C. (8)
Washington State (139)
Wisconsin (9)
48,734 Results for "43".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of the pharma.
September 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
July 29, 2026
·
1 min read
Press Releases
Carestream Launches NEW Lux HD 35 and Lux HD 43 Detectors for Medical Imaging
June 10, 2026
·
2 min read
Lung cancer
Pfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buy
Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.
June 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS)
September 17, 2026
·
2 min read
Radiopharmaceuticals
Regeneron enters radiopharma ring with up to $4.3B Telix alliance
Telix is Regeneron’s entry ticket into the radiopharma game, helping to better round out the company’s cancer portfolio, according to Truist Securities.
April 13, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
May 12, 2026
·
5 min read
Press Releases
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
May 22, 2026
·
5 min read
Press Releases
Cancer Biomarkers Market Size Worth USD 43.05 Bn by 2034 Powered by Expanding Use of Liquid Biopsy Technologies
December 9, 2025
·
1 min read
Press Releases
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
January 15, 2026
·
3 min read
1 of 4,874
Next
